Irish plant for Wuxi Biologics
Print Edition
HONG Kong-listed biopharma technology service provider Wuxi Biologics will invest 325 million euros (US$390 million) for a new biologics drug manufacturing facility in Ireland, the first overseas investment of its kind for a Chinese pharma company.
The 260,000-square-meter manufacturing site will be located at an industrial park in Dundalk in northern Ireland and is expected to create 400 new jobs and 700 construction jobs in phases over five years.
The site will begin construction in the first quarter in 2019 and be complete by the second quarter of 2021.
“Wuxi Biologics is a strong addition to Ireland’s growing cluster of next-generation bio-pharmaceutical companies and it also shows great commitment to Ireland with this project,” said Martin Shanahan, CEO of the Industrial Development Authority of Ireland, on Monday.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
